ADVFN ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Icon for charts Registrieren Sie sich für Echtzeit-Charts, Analysetools und Preise.
Denali Therapeutics Inc

Denali Therapeutics Inc (DNLI)

26,08
0,10
( 0,38% )
Aktualisiert: 17:05:04

Denali Therapeutics Inc (DNLI) Aktie

Echtzeit-Diskussionen und Handelsideen: Handeln Sie mit Zuversicht mit unserer leistungsstarken Plattform.

Premium

Wichtige Statistiken und Details

Current Price
26,08
( 0,38% )
Gebot
26,10
Fragen
26,12
Volumen
262.343
25,7701 Tagesbereich 26,80
12,58 52-Wochen-Bereich 26,80
Marktkapitalisierung
Handelsende
25,98
Handelsbeginn
26,23
Letzte Trade
1
@
26.11
Letzter Handelszeitpunkt
17:05:04
Finanzvolumen
US$ 6.891.999
VWAP
26,2709
Durchschnittliches Volumen (3 Mio.)
US$ 1.805.297
Ausgegebene Aktien
158.709.737
Dividendenrendite (LTM)
Kurs-Gewinn-Verhältnis
-8,88
Gewinn pro Aktie (EPS)
-2,88
Erlöse (LTM)
-
Nettogewinn (LTM)
-508,02M

Über Denali Therapeutics Inc

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor prog... Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson’s and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company’s OTV programs also comprise DNL628 targeting tau for Alzheimer’s disease; and DNL422 targeting alpha synuclein for Parkinson’s disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer’s disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California. Mehr anzeigen

Sektor
Healthcare
Branche
Biotechnology & Life Sciences
Hauptsitz
South San Francisco, United States
Gegründet
2026
Denali Therapeutics Inc is listed in the Healthcare sector of the NASDAQ with ticker DNLI. The last closing price for Denali Therapeutics was US$25,98. Over the last year, Denali Therapeutics shares have traded in a share price range of US$ 12,58 to US$ 26,80.

Denali Therapeutics currently has 158.709.737 shares in issue. The market capitalisation of Denali Therapeutics is US$4,14 billion. Denali Therapeutics has a price to earnings ratio (PE ratio) of -8.88.

Option-Flow Denali Therapeutics (DNLI)

Gesamtfluss

Bullisch

Nettoprämie

45k

Calls / Puts

100,00%

Käuf. / Verkä.

100,00%

OTM / ITM

0,00%

Sweeps

0,00%

DNLI Neueste Nachrichten

Zeitraum †ÄnderungÄnderung %HandelsbeginnHochNiedrigDurchsch. VolumenVWAP
11.255.0342327829224.8326.824.59260551825.60974265CS
46.3832.38578680219.726.819.19211524123.10936735CS
126.7134.641197728419.3726.817.71181088220.87687983CS
269.4256.542617046816.6626.815.34175751320.41532294CS
5212.0285.490753911814.0626.812.58173268917.96966369CS
156-3.27-11.141396933629.3533.3310.57128474519.0224362CS
260-53.15-67.083175564879.2379.510.57102721322.74956474CS

DNLI - Frequently Asked Questions (FAQ)

What is the current Denali Therapeutics Inc share price?
The current share price of Denali Therapeutics Inc is US$ 26,08
How many Denali Therapeutics Inc shares are in issue?
Denali Therapeutics Inc has 158.709.737 shares in issue
What is the market cap of Denali Therapeutics Inc?
The market capitalisation of Denali Therapeutics Inc is USD 4,14B
What is the 1 year trading range for Denali Therapeutics Inc share price?
Denali Therapeutics Inc has traded in the range of US$ 12,58 to US$ 26,80 during the past year
What is the PE ratio of Denali Therapeutics Inc?
The price to earnings ratio of Denali Therapeutics Inc is -8,88
What is the registered address of Denali Therapeutics Inc?
The registered address for Denali Therapeutics Inc is 161 Oyster Point Boulevard, South San Francisco, California, 94080
What is the Denali Therapeutics Inc website address?
The website address for Denali Therapeutics Inc is www.denalitherapeutics.com
Which industry sector does Denali Therapeutics Inc operate in?
Denali Therapeutics Inc operates in the Biotechnology & Life Sciences sector

DNLI Trades

Mehr

Trades verzögert

Um Echtzeit-Trades zu erhalten, aktualisieren Sie Ihr Konto

Auf Echtzeit aktualisieren
Keine Diskussionen Gefunden.
Neuen Thread Erstellen